The Biosimilars Council works to increase patient access to lifesaving, affordable biosimilar medicines. Leveraging our deep relationships on Capitol Hill, in federal agencies like FDA and CMS, and in the states, we strive to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, providing billions in savings to patients and the health care system. Our members include biosimilar manufacturers and stakeholders working to promote biosimilar products in the U.S. market.
The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org.
“Biosimilars hold the key to ensuring affordable access to biologic-alternatives medicines for all consumers. We exist to educate, advocate, and promote the development of these products.”
– Biosimilars Council Executive Director,
Christine Simmon | Executive Director, Biosimilars Council
Executive Vice President, Policy and Strategic Alliances, Association for Accessible Medicines (AAM)
Christine Simmon joined the Association for Accessible Medicines (AAM) in 2012 and is the Executive Vice President, Policy and Strategic Alliances. Christine also serves as Executive Director of the Biosimilars Council, the AAM subsidiary that advocates for greater access for patients to biosimilar medicines.
In her current role, Christine is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups.
Christine had previously served as Vice President of Policy, Public Affairs & Development at AAM from 2002 to 2006 and Senior Vice President of Policy & Strategic Alliances from 2012 to 2021. Before rejoining the association, she was the Senior Director of Public Policy for CVS Caremark, where she was the policy lead for the integrated retail, convenient care clinic and pharmacy benefit manager enterprise at both the state and federal levels. Previously, Christine was a Senior Policy Analyst at BlueCross BlueShield Association, where she helped position the insurer as a leading voice on pharmaceutical cost and safety issues.
Christine received her J.D. from Georgetown University Law Center and her B.A. in American Studies from Georgetown University.
Steven Selde | Director, Biosimilars Council
Steven Selde works with leadership to identify issues affecting Biosimilars Council members’ interests and develop and implement advocacy strategies and tactics that effectively support those interests.
Prior to joining the Association for Accessible Medicines (AAM), Steven was Assistant Director, Government Affairs, for the Ambulatory Surgery Center Association (ASCA). In this role he represented ambulatory surgery centers before Congress and federal agencies. Prior to his work with ASCA, he served as legislative counsel for Senator Deb Fischer (R., Neb.); there, he was responsible for developing and progressing the senator’s policy positions on health care, education, labor, Veterans Affairs and Indian Affairs. Steven developed and executed strategies to enact Senator Fischer’s legislation, including the Communities Helping Invest through Property and Improvements Needed for Veterans Act (H.R.5099/S.3364), Strong Families Act (S.1716) and Veterans Fair Debt Notice Act (S.2248), all signed into law.
Steven attended Creighton University School of Law and received his BA from Fordham University.